hepatorenal

Two of 4 patients with hepatorenal syndrome ( HRS) were improved and cured after treatment with MARS.

4例合并肝肾综合征（HRS）患者中，2例经MARS治疗病情好转，肾功能改善。

Objective: Hepatorenal syndrome ( HRS) is characterized by functional renal failure in end-stage liver disease.

目的：肝肾综合征是终末期肝病患者在无肾脏原发病变的情况下发生的一种功能性肾衰竭。

Treatment of 16 Patients with Hepatorenal Syndrome by Ascites Back Transfusion

腹水回输治疗肝肾综合征16例

Objectives To investigate the surgical techniques, clinical experiences and therapeutic effects of simultaneous hepatorenal transplantation.

目的探讨肝肾联合移植的手术技术 、 治疗经验及疗效.

Distribution of the Vascular Activated Substance And Its Function in the Development of Hepatorenal Syndrome

血管活性物质分布及其在肝肾综合征发病中的作用

Albumin dialysis combined with noradrenalin in the treatment of severe hepatitis with type 1 hepatorenal syndrome

白蛋白透析联合去甲肾上腺素治疗重型肝炎Ⅰ型肝肾综合征临床研究

MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to lier transplantation.

题目:MELD评分及临床类型预测肝肾综合症的预后: 同肝移植的相关性.

Methods 13 severe hepatitis patients with hepatorenal syndrome were treated with plasma exchange and hemofiltration compared to 13 with conventional medicine therapy.

方法应用血浆置换加持续血液滤过治疗13例重型肝炎合并肝肾综合征患者并与单纯药物治疗进行比较。

Clinical Research on Hepatorenal Syndrome Treated by Octreotide Combined with Dopamine

奥曲肽联合多巴胺治疗肝肾综合征的临床研究

Hepatorenal syndrome ( HRS ) is a well-recognized complication of end-stage lier disease.

肝肾 综合征 是一项肝病晚期普遍的并发症.

All children were testified without hepatorenal dysfunction, endocrine disease, musculoskeletal disorders and had not taken medicine which effect on metabolism.

所有患儿在术前检查时均已证实无肝肾功能异常，无内分泌疾患，未服用影响代谢的药物，也无其他可影响运动的骨骼肌肉疾病。

Author also discussed the prevention and treatment of hepatorenal syndrome according to its pathogenesis and evidence-based therapies.

还从这两个病例的治疗过程讨论如何根据肝肾综合征的发病机制和应用循证医学证据进行防治。

Hepatorenal syndrome ( HRS) is a well-recognized complication of end-stage liver disease.

肝肾综合征是一项肝病晚期普遍的并发症。

Detection of serum erythropoietin level in patients with hepatorenal syndrome and its clinic significance

肝肾综合征病人血清促红细胞生成素水平的测定及其临床意义

Measurement and Action of Plasma Leukotriene C_4 in Patients with Hepatorenal syndrome

肝肾综合征患者血浆白三烯C4检测及其作用

Therapy for hepatorenal syndrome

肝肾综合征的治疗

Objective : To study the effectiveness of ascites back transfusion treating hepatorenal syndrome.

目的: 研究用腹水回输方法综合治疗肝肾综合征的疗效.

Measurement of Urinary TXB 2,6 Keto PGF 1 α in Patients with Hepatorenal Syndrome and Its Clinical Significance

肝肾综合征患者尿TXB2、6-Keto-PGF（1）α测定的临床意义

Cox regression analysis of predictive factors of hepatorenal syndrome

Cox回归分析对肝肾综合征预后因素的评估

The incidence rate of hepatorenal syndrome in treatment group was obviously lower than that in control group ( P0.05).

治疗组中肝肾综合征的发生率明显低于对照组（P0.05）。

Plasma levels of atrial natriuretic peptide in patients with hepatorenal syndrome

肝肾综合征患者血浆心钠素水平的变化

Objective study the effectiveness of ascites back transfusion treating hepatorenal syndrome.

目的研讨用腹水回输为主综合治疗肝肾综合征的疗效.

The influence of prostaglandin to plasma tumor necrosis factor-α, nitric oxide and endotoxin in patients with hepatorenal syndrome

前列地尔对肝肾综合征患者血浆TNF-α、NO及内毒素水平的影响

Methods retrospectively analyze the data of treatment of hepatorenal syndrome by ascites back transfusion combined with vaso-active substance.

方法回顾性分析我院近年来以腹水直接回输，合并使用血管活性药物治疗肝肾综合征的资料。

Objective To investigate the predictive factors and the best prognostic parameter of hepatorenal syndrome ( HRS).

目的探讨影响肝肾综合征（HRS）预后的参数及最佳预后指标。

During period of hospitalization refractory ascites occurred in 1 case, hepatorenal syndrome in 1.

住院期间发生顽固性腹水、肝肾综合征各1例。

Effect observe of terlipressin on hepatorenal syndrome

特利加压素治疗肝肾综合征的疗效观察

Clinical study of patients with hepatorenal syndrome treated with Lipo pge1.

1治疗肝肾综合征的临床研究。

Objective: To study the effectiveness of ascites back transfusion treating hepatorenal syndrome.

目的：研究用腹水回输方法综合治疗肝肾综合征的疗效。

Hepatorenal syndrome ( HRS) is a common complication of serious liver disease with a very high mortality.

肝肾综合征（HRS）是严重肝病常见并发症，病死率极高。